Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  hormone therapy
Trial Status:  Active
Results 1-25 of 8737 for your search:
Start Over
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ISSFASL0042, NCT02000193
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000649028, FRE-FNCLCC-GETUG-18/0706, 2008-A00529-46, EU-20966, FNCLCC-GETUG 18/0706, NCT00967863
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13P.461, 2013-027, NCT02023463
Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy
Phase: Phase II
Type: Treatment
Status: Active
Age: over 21
Sponsor: Other
Protocol IDs: 30296-A, L-8863, 06-2040-A-02, NCT00223665
Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI, Other
Protocol IDs: CDR0000064184, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, PR8, NCT00002651
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 082013-032, NCT02064582
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11D.243, 2011-32, NCT01420250
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEP12-UC-0101/1104, NCT01780220
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1207, U10CA032102, NCI-2012-01995, SWOG-S1207, NCT01674140
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCCA_Deg01, NCT01630967
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2013-083, NCI-2014-00212, 1311012529, P30CA022453, NCT02058706
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A-38-52014-194, NCT01753297
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 11595, IRUSANAS0092, NCT00921115
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR103305, ARN-509-002, NCT01790126
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BCCT2014001, NCT02062489
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RJBC1401, NCT02344940
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
Phase: Phase III
Type: Treatment
Status: Active
Age: 45 to 80
Sponsor: Other
Protocol IDs: BMI, NCT01758146
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 50
Sponsor: Other
Protocol IDs: KBCSG012, NCT01622361
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: RenJiH-BC-002, NCT02221999
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 42
Sponsor: Other
Protocol IDs: IBCSG 48-14/BIG 8-13, NCT02308085
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: EER001, NCT02238808
Start Over